Dachaigh › Lymphoma Cealla B Mòr Sgaoilte
Sgrùdaidhean clionaigeach Lymphoma Cealla B Mòr Sgaoilte a’ fastadh anns na SA
Tha 101 sgrùdaidhean airson Lymphoma Cealla B Mòr Sgaoilte a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- New York City, NY21 sgrùdaidhean
- Baldwin Park, CA19 sgrùdaidhean
- Chicago, IL18 sgrùdaidhean
- Houston, TX17 sgrùdaidhean
- Los Angeles, CA17 sgrùdaidhean
- Milwaukee, WI16 sgrùdaidhean
- Boston, MA16 sgrùdaidhean
- Nashville, TN15 sgrùdaidhean
- Philadelphia, PA15 sgrùdaidhean
- Portland, OR15 sgrùdaidhean
- Durham, NC14 sgrùdaidhean
- Dallas, TX13 sgrùdaidhean
- Washington, DC12 sgrùdaidhean
- Seattle, WA12 sgrùdaidhean
- Salt Lake City, UT12 sgrùdaidhean
- Cincinnati, OH11 sgrùdadh
- Cleveland, OH11 sgrùdadh
- Denver, CO11 sgrùdadh
- Rochester, MN10 sgrùdaidhean
- Richmond, VA10 sgrùdaidhean
- Atlanta, GA10 sgrùdaidhean
- Cedar Rapids, IA9 sgrùdaidhean
- Edison, NJ9 sgrùdaidhean
- Omaha, NE9 sgrùdaidhean
- Columbus, OH9 sgrùdaidhean
- Greenburgh, NY8 sgrùdaidhean
- Jacksonville, FL8 sgrùdaidhean
- Grand Rapids, MI8 sgrùdaidhean
- Louisville, KY8 sgrùdaidhean
- San Francisco, CA8 sgrùdaidhean
- San Antonio, TX8 sgrùdaidhean
- New Haven, CT8 sgrùdaidhean
- St. Louis, MO8 sgrùdaidhean
- Sacramento, CA8 sgrùdaidhean
- Miami, FL7 sgrùdaidhean
- Kansas City, MO7 sgrùdaidhean
- Indianapolis, IN7 sgrùdaidhean
- Aurora, CO7 sgrùdaidhean
- Charlottesville, VA7 sgrùdaidhean
- Buffalo, NY6 sgrùdaidhean
Le stàit
- Alabama4 sgrùdaidhean
- Arizona13 sgrùdaidhean
- Arkansas4 sgrùdaidhean
- California42 sgrùdaidhean
- Colorado19 sgrùdaidhean
- Connecticut8 sgrùdaidhean
- Florida23 sgrùdaidhean
- Georgia15 sgrùdaidhean
- Idaho4 sgrùdaidhean
- Illinois22 sgrùdaidhean
- Indiana9 sgrùdaidhean
- Iowa11 sgrùdadh
- Kansas7 sgrùdaidhean
- Kentucky11 sgrùdadh
- Louisiana6 sgrùdaidhean
- Maryland13 sgrùdaidhean
- Massachusetts16 sgrùdaidhean
- Michigan15 sgrùdaidhean
- Minnesota16 sgrùdaidhean
- Missouri8 sgrùdaidhean
- Montana4 sgrùdaidhean
- Nebraska9 sgrùdaidhean
- Nevada3 sgrùdaidhean
- New Jersey13 sgrùdaidhean
- New Mexico3 sgrùdaidhean
- New York31 sgrùdaidhean
- North Carolina20 sgrùdaidhean
- North Dakota4 sgrùdaidhean
- Ohio23 sgrùdaidhean
- Oklahoma5 sgrùdaidhean
- Oregon15 sgrùdaidhean
- Pennsylvania19 sgrùdaidhean
- Sgìre Cholumbia4 sgrùdaidhean
- South Carolina4 sgrùdaidhean
- South Dakota3 sgrùdaidhean
- Tennessee19 sgrùdaidhean
- Texas29 sgrùdaidhean
- Utah14 sgrùdaidhean
- Virginia17 sgrùdaidhean
- Washington17 sgrùdaidhean
- Wisconsin19 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05006716Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06834373Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06500273Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06863402Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT07763210Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06649812Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
A’ fastadhSgrùdadh amharc
Aoisean 0 gu 38 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06131801Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT06977711Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
A’ fastadhÌre 2
Aoisean 65 gu 99 · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT05952024Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT03418038Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
A’ fastadhÌre 1/2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT03223610A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
A’ fastadhÌre 2/3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT05139017A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06717347A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07519772A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06890884A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06091865Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07226843Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
A’ fastadhÌre 1/2
6 Months – 25 Years · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT06395103Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT04002947Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 16 Sult 2026 · NCT05757219A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Sult 2026 · NCT07195916Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Sult 2026 · NCT06806033Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Sult 2026 · NCT05272384Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.